<SEC-DOCUMENT>0001019687-14-002686.txt : 20140709
<SEC-HEADER>0001019687-14-002686.hdr.sgml : 20140709
<ACCEPTANCE-DATETIME>20140709160518
ACCESSION NUMBER:		0001019687-14-002686
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140707
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140709
DATE AS OF CHANGE:		20140709

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RestorGenex Corp
		CENTRAL INDEX KEY:			0001053691
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-AMUSEMENT & RECREATION SERVICES [7900]
		IRS NUMBER:				300645032
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-24477
		FILM NUMBER:		14967363

	BUSINESS ADDRESS:	
		STREET 1:		1800 CENTURY PARK EAST, 6TH FLOOR
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90067
		BUSINESS PHONE:		310.526.8700

	MAIL ADDRESS:	
		STREET 1:		1800 CENTURY PARK EAST, 6TH FLOOR
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90067

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Stratus Media Group, Inc
		DATE OF NAME CHANGE:	20080722

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FERIS INTERNATIONAL, INC.
		DATE OF NAME CHANGE:	20080228

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TITAN MOTORCYCLE CO OF AMERICA INC
		DATE OF NAME CHANGE:	19980615
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>restorgenex_8k-070914.htm
<DESCRIPTION>FORM 8K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">WASHINGTON, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CURRENT REPORT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">PURSUANT TO SECTION 13 OR 15(d) OF THE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">SECURITIES EXCHANGE ACT OF 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Date of Report (Date of earliest event reported):
July 7, 2014</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">RESTORGENEX CORPORATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; text-align: center">NEVADA</TD>
    <TD STYLE="width: 34%; text-align: center">000-24477</TD>
    <TD STYLE="width: 33%; text-align: center">30-0645032</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(State or other jurisdiction of incorporation)</TD>
    <TD STYLE="text-align: center">(Commission File Number)</TD>
    <TD STYLE="text-align: center">(IRS Employer Identification No.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">1800 Century Park East, 6<SUP>th</SUP> Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Los Angeles, California 90067</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(805) 884-9977</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Registrant&rsquo;s telephone number, including
area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instruction
A.2. below):</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Wingdings">o</FONT></TD><TD>Written communications pursuant to Rule 425 under the Securities Act of 1933 (17 CFR 230.425)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Wingdings">o</FONT></TD><TD>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Wingdings">o</FONT></TD><TD>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Wingdings">o</FONT></TD><TD>Pre-commencement communications pursuant to Rule 13e-4(e) under the Exchange Act (17 CFR 240.13e-4(c))</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.75in; text-align: justify; text-indent: -0.75in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 10%"><B>Item&nbsp;5.02&#9;&nbsp;</B></TD>
    <TD STYLE="width: 90%"><B>Departure of Directors or Certain Officers; Election of Directors; &#9;Appointment of Certain Officers;
    Compensatory Arrangements of Certain Officers</B></TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.75in; text-align: justify; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Effective July 7, 2014, Jerold Rubinstein
resigned as a director of RestorGenex Corporation (the &ldquo;Company&rdquo;). The resignation was not pursuant to any disagreement
with the Company, but was tendered in connection with the change of the focus of the Company to a specialty biopharmaceutical company
and the Company&rsquo;s need for a majority independent board for purposes of applying to NASDAQ. Mr. Rubinstein will serve as
a consultant to the board of directors.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 10%"><B>Item&nbsp;8.02&#9;&nbsp;</B></TD>
    <TD STYLE="width: 90%"><B>Other Events</B></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">On July 9, 2014, the Company issued a
news release regarding the foregoing. A copy of the news release is furnished as Exhibit 99.1 hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: left"><B>&nbsp;</B><TABLE CELLPADDING="0" CELLSPACING="0"
STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align:
left"><TD STYLE="width: 10%"><B>Item&nbsp;9.01&nbsp;</B></TD>
    <TD STYLE="width: 90%"><B>Financial Statements and
Exhibits</B></TD></TR></TABLE>


</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: left"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: left; text-indent: 0.5in">(d) Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 9%; text-align: center"><U>Exhibit No.</U></TD>
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 84%"><U>Description</U></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: center">99.1</TD>
    <TD>&nbsp;</TD>
    <TD>News release issued by Company
on July 9, 2014.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: left"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 47%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 53%; padding-right: 5.4pt; padding-left: 5.4pt; text-indent: 0.9pt"><FONT STYLE="font-size: 10pt">RESTORGENEX CORPORATION</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-indent: 0.9pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-indent: 0.9pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Dated:&nbsp;&nbsp;July 9, 2014</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">By:&#9;<U>/s/ Stephen M. Simes&#9;</U></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U></U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stephen M. Simes,
Chief Executive Officer</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>restorgenex_8kex9901.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: Red"><B></B></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; color: Red"><B></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: Red"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><IMG SRC="logo.jpg" ALT="">&nbsp;</B></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; color: Red"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 33%"><B>FOR IMMEDIATE RELEASE</B></TD>
    <TD STYLE="width: 34%"><B>&nbsp;</B></TD>
    <TD STYLE="width: 33%; text-align: right"><B>OTC QB: RESX</B></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">RestorGenex Announces
Management Changes</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: #604ADC">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><FONT STYLE="color: #343434"><B>CHICAGO,
</B></FONT><B>Illinois (July 8, 2014)</B> - RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company initially
focused on developing products for dermatology, ophthalmology and women&rsquo;s health, announced today several management changes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">RestorGenex has appointed Phillip B.
Donenberg as its chief financial offer. Mr. Donenberg has served biotech and pharmaceutical companies in financial positions for
over 20 years. Before RestorGenex, he served as BioSante Pharmaceuticals, Inc.&rsquo;s Senior Vice President of Finance from 2010
until June 19, 2013 and Chief Financial Officer and Secretary from 1998 until June&nbsp;19, 2013 when BioSante merged with ANIP
Acquisition Company, d/b/a ANI Pharmaceuticals, Inc. BioSante, whose stock was listed on the NASDAQ Global Market, was a specialty
pharmaceutical company focused on developing products for women&rsquo;s and men&rsquo;s health and oncology. From 1995 to 1998,
Mr.&nbsp;Donenberg was Controller of Unimed Pharmaceuticals, Inc. (currently a wholly owned subsidiary of AbbVie Inc.), a company
with a product focus on infectious diseases, AIDS, endocrinology and oncology. Prior to Unimed Pharmaceuticals, Inc., Mr.&nbsp;Donenberg
held similar positions with other pharmaceutical companies. Mr.&nbsp;Donenberg earned his BS in Accountancy from the University
of Illinois Champaign-Urbana, College of Business and is a Certified Public Accountant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">&quot;We are pleased to have Phil as
our CFO,&quot; said Stephen M. Simes, RestorGenex&rsquo;s chief executive officer. &ldquo;I have worked with Phil for over 20 years
and know him to be a dedicated and committed person who is well schooled in all aspects of accounting and finance in publicly traded
biotech and pharma companies.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">In other developments, RestorGenex has
appointed Yael Schwartz, PhD as its Executive Vice President of Preclinical Development. Previously, Dr. Schwartz was president
of RestorGenex&rsquo;s Canterbury/Hygeia wholly owned subsidiaries. Dr. Schwartz has more than 25 years&rsquo; experience in drug
discovery and product development. From 1998 to 2007, Dr. Schwartz had positions of increasing responsibility at Sepracor, Inc.
(now Sunovion) where she played key leadership roles on teams that launched three drugs that are currently in clinical practice
for the treatment of asthma (Xopenex), insomnia (Lunesta) and chronic obstructive pulmonary disease (Brovana). Prior to that, she
contributed to the development of drugs for the treatment of urinary bladder cancer (Valstar) and hypertension (Carvedilol). Since
2007, Dr. Schwartz has been the Founder, President, CEO and Director of Hygeia. Dr. Schwartz adapted and streamlined development
strategies and budgets to ensure effective achievement of scientific and business objectives. Dr. Schwartz received her doctorate
degree with honors in Endocrine Physiology from a joint program at the University of Massachusetts Medical School and Worcester
Polytechnic Institute (WPI).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">In addition, RestorGenex announced that
David Sherris, Ph.D.&rsquo;s new title is Chief Scientific Officer of RestorGenex.&nbsp; Previously, Dr. Sherris was Chief Scientific
Officer and President of RestorGenex&rsquo;s Paloma/VasculoMedics wholly owned subsidiaries.&nbsp; Dr. Sherris was the founder
and CEO of both Paloma Pharmaceuticals, Inc. and VasculoMedics, Inc. He has over 30 years of experience in biopharmaceuticals and
diagnostics.&nbsp; Dr. Sherris was CEO and founder of a consulting/out-sourcing concern, Sherris Pharma Partners, with a focus
on business development and R&amp;D strategy, including a niche focus in angiogenesis and vascular targeting.&nbsp; In addition,
Dr. Sherris has worked with venture capital companies where he has both advised and raised seed money for biotech startups.&nbsp;
Prior to his starting Sherris Pharma Partners, Dr. Sherris had been employed by pharmaceutical and biotechnology companies to manage
external R&amp;D (academic groups and contract research organizations) to augment and expand internal scientific programs, and
to lead internal pharmaceutical development teams.&nbsp; Dr. Sherris has been a frequently invited guest speaker at biopharmaceutical
business and scientific conferences, a published author and holder of patents in a wide range of therapeutic areas.&nbsp; Dr. Sherris
has held positions of increasing responsibility at Centocor, Unilever Research, Serono and OXiGENE where he was Chief Operating
Officer and Vice President of Research and Development, as well as Chief Operating Officer of a joint venture between OXiGENE and
Peregrine Pharmaceuticals called Arcus LLC.&nbsp; Dr. Sherris received his Ph.D. in Biochemistry and Molecular Genetics from the
University of Utah, held a postdoctoral position in cellular immunology at the Jackson Laboratory and a faculty position in the
Department of Medicine, Division of Clinical Immunology at the Mt. Sinai Medical Center, New York, NY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">RestorGenex also announced today that
Jerold Rubinstein, former CEO and chair of the audit committee, resigned from the RestorGenex board of directors as part of the
company&rsquo;s efforts to achieve a majority of independent directors in anticipation of an application to list the company&rsquo;s
common stock on the NASDAQ Stock Market. Mr. Rubinstein will remain a senior advisor to the RestorGenex board of directors for
at least the next year. Sol Barer, chairman of the board of RestorGenex said, &ldquo;We express our gratitude and appreciation
to Jerry for his years of service to RestorGenex and his commitment to RestorGenex and our near-term objective to obtain a NASDAQ
listing for our common stock. We look forward to his continued guidance in an advisory role.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>About RestorGenex Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">RestorGenex Corporation is a specialty biopharmaceutical
company initially focused on developing products for dermatology, ophthalmology and women&rsquo;s health. The Company&rsquo;s prescription
dermatology business primarily is based upon three compounds under development for the treatment of aging skin fragility/thinning,
androgen excess, e.g. acne, hirsutism (unwanted excess hair), and keloid scarring. The Company&rsquo;s ophthalmology product will
target age-related macular degeneration, based on inhibition of the PI3K/Akt/mTOR&nbsp;pathway. The Company&rsquo;s prescription
women&rsquo;s health business is based upon a &ldquo;soft&rdquo; estrogen compound under development for vulvar and vaginal atrophy
(VVA), a condition affecting peri- and post-menopausal women due to declining levels of estrogen. www.restorgenex.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain statements in this release are forward-looking
statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements
about RestorGenex&rsquo;s intent to list its common stock on the NASDAQ Stock Market and other statements that are not historical
in nature, particularly those that utilize terminology such as &ldquo;will,&rdquo; &ldquo;intends,&rdquo; &ldquo;expects,&rdquo;
&ldquo;plans,&rdquo; &ldquo;potential,&rdquo; &ldquo;future,&rdquo; &ldquo;believes,&rdquo; &ldquo;continue,&rdquo; other words
of similar meaning, derivations of such words and the use of future dates. Forward-looking statements by their nature address matters
that are, to different degrees, uncertain. Uncertainties and risks may cause RestorGenex&rsquo;s actual results to be materially
different than those expressed in or implied by such forward-looking statements. Particular uncertainties and risks include, among
others, the failure of the RestorGenex to achieve a NASDAQ listing for its common stock, and other risks and uncertainties described
in RestorGenex&acute;s filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K/A
and subsequent quarterly report on Form 10-Q. All forward-looking statements in this release speak only as of the date of this
release and are based on RestorGenex&acute;s current beliefs and expectations. RestorGenex undertakes no obligation to update or
revise any forward-looking statement, whether as a result of new information, future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Contact:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">RestorGenex Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Tim Boris, 310-526-8700<FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">tboris@restorgenex.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr>
    <td>&nbsp;</td></tr>
</table>
<P STYLE="margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``8$!08%!`8&!08'!P8("A`*"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!#`0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P``1"`"F`J`#`2(``A$!`Q$!_\0`
M'0`!`0`"`P$!`0````````````<%!@,$"`(!"?_$`$H0``$#`P$&`@<#"`8(
M!P`````!`@,$!081$A@A5933!S$3%$%188&1"")Q%3(S-T*AL<$T4F)RDK(7
M-D-$5&-S='6%HK.TT>'_Q``9`0$!`0$!`0```````````````@$#!`7_Q``R
M$0$``0$'`00)!`,``````````0(#!!$2%2%2,3)!46$3%'&!D:&QT>$BP?#Q
M!3-"_]H`#`,!``(1`Q$`/P#U2````````````````````````#C?/%'^DE8W
M^\Y$/E*NF5=$J(57X/0W"68PY@$5%35%14]Z`QH`````````````````````
M````````````````````````````````````````````````````````````
M````````````````<=340TL+I:F5D43?-SW(B(.IT<@-.K\ZIW2K3V.DGN51
MY(K&JC$_FICI+=F%^_IM3';:9W^S8[1=/P3BOS4]$7>KK7.7V_9PF\1THC'V
M?=MUTO\`:[7JE;6Q,>G["+M.^B<34[EXDT\>K;?122K['S.V$^G%3L4'AS;H
MOO5M345+_-4148B_3C^\V.AQRT4.GJUOIVN_K.;M+]5U+B;O1XU?)$^GK\*?
MFF\^89'<55*1%C:OLIH%<OU74Z<U%E5=QFANLJ+_`%E<B?35"T-:C4T:B(GN
M1#]+B^13V*(A,W2:NW7,H9)C-\\WVNK=\M?YG0J;;64FOK-%40Z>U\2HGUT/
M005$5-%XH7'^1J[Z43<*>Z7GRDKJJD>CZ2JGA<GMCD5#>L3SN?UF.DO:M?&]
M4:VI1-%:OLVO9I\3:[SBEINC7+)3-AF7RFA39<B_P7YDGR2R5%CN#J6H5'L<
MFU'*B:(]O\E]Z'>FTL;U&68W<*J+6[3FB=EV!B\6J7U>.6Z>1=7O@;M+[U1-
M/Y&4/D51EF8E]6F<T1(`#&@`````````````````````````````````````
M`````````````````````````````````````````=*6[6Z*1T<M=2LD:NCF
MNE:BHOQ34V(F>C)F(ZNZ#KTM=25;E;2U4$SDXJD<B.5/H=@3$QU(F)Z``,:`
M``<57504<#IZJ:.&)OF][M$05'IO1Z4Z,](O#5^NB?'1//\``Z45G@6H;45J
MNK*EO%KYN*,_NM\F_P`?B5$1UE,S/2&-EO%SN?W,?H=F)>'KM8BL9^+6_G._
M<<,6'QU4S:C(*V>YSIQ1CEV(F_@U#:@7Z::=J-OK\4>BBK>O?Z?!P4E)3T<2
M14D$<,:?LQM1$.<`Y3..\NL1AT`?,LC(8GRS/;'&Q%<Y[ET1J)YJJ^Q#6'>(
MF'->K'9/9T<BZ:>ML_\`LV*9GI#)F(ZMI!PT573UU+'4T4\513R)JR6)Z/:Y
M/@J<%.8QH``!I/BO3I)8Z:=&ZRQ3HUOO7:14T^J(;L8^[6Y+C+0I+L^@@F2=
MS5_:<U%V4_#5=?D=;&O)7%7@YVU&>B:?%]6*D6@LU%2N_.BA:UWXZ<?WG>`.
M<SC.,KB,(P@`!C0`````````````````````````````````````````````
M````````````````````````````````-#L5DMUVO^2.N-)'.Z.LT:KM>"*G
MP-\)W;;777'(,B=0W::WHRKT<V-NNVNGFO$]-ATJWPV_=Y[?K3MC_3L9#9J&
MQ7*Q5=H@2FF=6-B<C'+]]J^:*FILF85D]!C5=54DGHYXV(K7:(NGWD]YJE9;
M:NT9+8Y[I7/NL4L_HF>EU:L3U\G(FNBFQY__`*GW/_II_F0Z5;U6<3./G[T4
M[4VF$8?TZ<5HR.6%CTR33::B_P!%;PU0RN25\UHQNIJV*V2HBC1&JY."N543
M73\5U,53V"\.IXG-R:J:BM143T#.'#R,QDC*)]AJHKM*L=(]J,?)[4U5$1?K
MH<ZIB:Z<9B8Q[H_$+IB8IG#&-N^?RP<EHR)E$ZI;D4CZAK/2>B2G;LJNFNAF
MJ*:MNF,PRHY:*OGA1=IS/T;_`'[*_P`#".L>04=,KJ3)'O;&S5C98&KJB)P1
M5,]C%PDNM@HJV9J-EECU<C?+5%T7^!MI/Z<T83OW1A^S+./U99QC;Q_+5:B+
M)(;[26Q;\BNJ(GRI)ZNW1NSIPT^9MEN95V^UO6Z5?KDT>T]TJ,1GW?/31#%7
M']8%H_[2;^*&;N_&U5J?\A_^53+2K-%,81OY1XRVSIRS5.,[>?DU6UTU_OM#
M%<EOCJ)E0BOC@BA148W7@FJ^?`R6-5E?'=*^T76H;534S62QSHS95['>]/>B
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MUOFC2*S27%T]KC27;V853ZIY)P4P5^ES"_\`BQ>K%C^5+9:.AHJ>H1GJD<R.
M5^J+Y\?9[SM>!E;>I+CF=LOUYJ+N^UW!M+'/-HG!&KKHGLU7V&%NECNU]\=<
MEBLF1U-ADBMM(Z22"!LJRHNJ(U4=Y:>94?[*IJF.GV9_Q&#?\'L&56BNJ9<F
MRO\`+E.^-&QQ>ILA]&[77:U;Y\.&AHGB9FV1XYXH-6WU#I,?MMOAK[C1)&U5
M="Z58WO1=-=6HK5\_84#",;OEBJ*M]\RRKOS)6M;&R>G9$D2HJZJFRO'75/H
M:Q)30UOV@[G2U4;9:>?&$BD8[R<U9U147Y$T3&>9G"=FU1.6(C;=F?%[(:JU
M>%=TO>/5B13MBBEIZAB(Y-ETC$U1%1475%_>9C,;C56_P]O%QI)5CK(+;+/'
M)HB[+TC5471>'F1')ZF>R>%.<8%<I'/J+)Z&2@D>O&>A?,Q8U^*M7[J_(L?B
M!^JF_P#_`(1-_P"THFB*<L>?RV,TSC[/NT;&\>\1[WCULNC?$;T*5M-'4)&M
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M!7T-/64<K9::>-LL4C?)S7)JBI\C;:F*:=HZ_+R+.9JG?N_F+G`!YG8`````
M````````````````````````````````````````````````````````````
M``````````Q%DM#K;7W:H=,DB5L_ID:C=-CAY?$RX*BJ8B8CO9-,3,3/<Q%^
MM#KI4VN5LR1I1U"3JBMUV]/9\#FR*W+=K+54+9$B69J-VU373BB^7R,B#8KJ
MC#R3-$3CYM2=:<C@@579)%''&WBYU*U$:B)YJIF:VCAON.K3NG])#50M5L[/
M;JB*CT_<I*_M/YDZPXA'9*.165MWVF2*U>+*=/S_`/%JC?P52O6ET3[51.IM
M/0+"Q8]/+9V4TT^1UKFK+3:3[MH1333C-'[M<=9LG?3K3NOU/Z%6["N2F3:T
M\O/WFPV>@CM=LIJ*!5='`Q&(J^:^]3N`YUVM5483]%4V<4SC#%U-J=-D='<T
ME1&T\+XECV>+MK3CK\C)O:CV.:Y-6N314]Z'Z"9JF<,>Y<4Q&.'>U&GQ^^VV
M/U:T7J..A:J^BCF@1[F(JZZ:F4QZRRVZ:JJZZK6LKZI6^DEV=E$1/)J)[C-`
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M&VSY%5,79?5-7T-%"O\`;F5./X-154S-MQJNK)&U>87!MQJ$7:;10-6.CA7X
M,\Y%3^L]5^"(7C73,U5=9_G1.%,QEAU/#^U911U,]5D.60WZBECV861T;84:
MY%XNVD\TTX'<BQ61GB;-E7K;5CDMC;?ZML<45)-O:VM?EIH;4B(B(B)HB>2(
M#G-<S,SXKBF,,$V\8/#),^;1S4=P2VU\+7023>C5Z30.5%6-R(J>3D14^9N.
M169UWQ&XV9LR1.JJ-]*DJMU1JN8K==/F9@#TE6$1X&2,9GQ2&VX%XC6VW4M#
M1>(4$=+31-AB9^2V+LL:FB)JJZKP0WF[6B^UF"/M$-YCCO<M,D$ER6']I4T>
M]&(J:*J:Z<>&ILH-JM:JIQG#X0R+.*>C`8OBEMQ_#J;'((6RT$<"PR(]/TVT
MGWW.^+E557\3I>&V+56&V.6S2W%*Z@AG>ZAVF*U\,+EU2-RZKM:+KQX>9M@)
MFN9QB>]66(``2T``````````````````````````````````````````````
M`````````````````````````````````!XO^TG<Y+CXL7&)[E6*ABBIHT7V
M)LH]?WO4J/V>/%6CJ+32XMD52RGKJ9J144\KM&SQIY,55\GIY)[TT]IH7VH<
M9J+5GJWI(W+076-JI(B<&RL:C7-7XJB(J?/W$;5-?,^U3946UA32^55:56-M
M,OZ0`\,8IXK9CC$3(+?=Y)J1O!M/6-],Q$]R:\4^2E#MGVEKS$B)<[#05'O=
M!*^)?HNT>*NXVD=-WKIOEG/79ZD!YZB^TU;U:GIL9K&K_8J6._BB'V_[3-L1
M/N8U7*OQJ&)_(Y>J6W%?K-EXO00/-%=]IJI=JE!C,3/<L]6KOW(U#7*CQVS^
M_P!3ZK8Z:EAE?P;'14CII/\`U*[^!<7*UGK&#)O5GW;O72JB(JJNB)[5-+RG
MQ0P_&4>VXWNF?.W_`'>F7TTGX:-UT^>A#*'PW\4\Z5LF57BJH*)W%6UDZJNG
MPA9P3YZ%0PSP(Q''E9-6P/O-8WCMUFGHT7X1IP^NIDV5E1VZL?9]VQ7:5]FG
M#VL!_I7R[-I74WAIBTC:=5V5N=PX1M^.GYORU<OP,M:/!^>[U,=P\3;]59#5
M-7:2C1ZLI8U]VRFFOT1/@5V&*.")D4$;(XF)HUC&HB-3W(B'V1-MAM9QA]?B
MN+/'>J<77M]%2VZDCI:"FAIJ:--ED4+$8UJ?!$.P`<'0````````````````
M````````````````````````````````````````````````````````````
M`````````````````8[(;);<BM4UMO5)%5T4R?>CD3V^Q47S14]BIQ//^5?9
MK59GRXK>FMC5=4IJ]JKL_!)&_P`T/2(.MG;UV79ESKLJ+3M0\95G@-GM.Y?1
MV^DJ6I[8JMG'_%HITV^"?B`YVGY"T^*U46G^8]L@]/K]IX0X>I6;QS1?9_SJ
MH<B306ZE1?;+5(NG^%%-LM'V9ZU[D6\Y%!$WVMI*=7K]7*G\#TT"*K[:SWX*
MBZ6<=R38_P"`6%6M6OK*>JNDJ>VKF79U_NMT3ZZE*M%FMMFIT@M%!2T4*<-B
MGB:Q/W)Q.^#SUVE=?:G%WIHII[,``(4`````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````````````````````````````````-?O
M.5T-HRS',>J8JEU;??6?5GQM:L;/01H]^VJJBIJB\-$7CYZ&P```````````
M````````````````````````````````````````````````````````````
M```````````````````````````````````````$J\1/U[>$?_F__P`5I530
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MRVD82V)B>@`#DT``````````````````````````````````````````````
M````````````````````````````````````````````````````````````
%```?_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
